Table 2 Characteristics of studies included in the systematic review of gastric cancer incidence in patients with intestinal metaplasia
From: Adenocarcinoma risk in gastric atrophy and intestinal metaplasia: a systematic review
First Author (year) [reference] | Country | Study Design | Indication for Endoscopy | Study follow up period | Outcome Source | Number of patients in cohort | Male (%) | Mean age (years) | Follow-up (years) [mean/median] | HP* positive (%) |
|---|---|---|---|---|---|---|---|---|---|---|
Bleibel (2003) [39] | United States of America | Retrospective cohort | NR* | 1993–2012 | Cancer registry | 675 | 49 | 61 | 5.3 (mean) | 18 |
De Vries (2010) [40] | The Netherlands | Prospective cohort | NR* | 2006–2007 | Endoscopy | 101 | 50 | 61 | 2.3 (mean) | 18 |
González (2016) [38] | Spain | Retrospective cohort | NR* | 1995–2013 | Pathology records, clinical records, endoscopy | 467 | 56 | 53 | 12 (mean) | 56 |
Horsley-Silva (2015) [26] | United States of America | Retrospective cohort | Dyspepsia | 2003–2004 | NR* | 200 | 50 | 68 | 4.1 (mean) | 19 |
Kim (2008) [27] | Korea | Prospective cohort | NR* | 1992–1998 | Endoscopy | 515 | 88 | 45 | 10.2 (mean) | 78 |
Li (2016) [18] | United States of America | Retrospective cohort | NR* | 1997–2013 | Cancer registry, clinical records | 4146 | 48 | 66 | 7.1 (median) | 51 |
Reddy (2014) [19] | United States of America | Retrospective cohort | NR* | 2000–2011 | Cancer registry | 907 | NR* | 68 | 4.6 (median) | NR* |
Song (2015) [36] | Sweden | Retrospective cohort | NR* | 1979–2011 | Endoscopy, Cancer registry, ONS* | 11,530 | 55 | 66 | 7.9 (mean) | NR* |
Tava (2006) [12] | Italy | Retrospective cohort | Dyspepsia | 1989–1997 | Endoscopy | 259 | 51 | 60 | 3.9 (median) | 27 |